Patch Testing on Dupilumab: Reliable or Not?

Alexandra Kuzyk; Alim R. Devani; Vimal H. Prajapati; Peter A. Lio

doi:10.12788/cutis.0471

Patch Testing on Dupilumab: Reliable or Not?

Alexandra Kuzyk, Alim R. Devani, Vimal H. Prajapati, Peter A. Lio

Research output: Contribution to journal › Comment/debate

1 Scopus citations

Original language	English
Pages (from-to)	158-159
Number of pages	2
Journal	Cutis
Volume	109
Issue number	3
DOIs	https://doi.org/10.12788/cutis.0471
State	Published - Mar 2022
Externally published	Yes

Access to Document

10.12788/cutis.0471

Cite this

@article{3bd2601a911346dd86bc0e244cecfa50,

title = "Patch Testing on Dupilumab: Reliable or Not?",

author = "Alexandra Kuzyk and Devani, {Alim R.} and Prajapati, {Vimal H.} and Lio, {Peter A.}",

note = "Funding Information: the Section of Community PCUTIS ediatrics and Section of Pediatric Rheumatology, Department of Pediatrics, University of Calgary. Dr. Lio is from the Department of Dermatology, Northwestern University Feinberg School of Medicine and Medical Dermatology Associates of Chicago, both in Chicago, Illinois. Dr. Kuzyk reports no conflict of interest. Dr. Devani reports receiving honoraria—for serving on advisory boards and speakers bureaus and participating in consultancy meetings and research—from one or more of the following: AbbVie, Arcutis Biotherapeutics, Bausch Health Companies, Galderma Laboratories, Janssen, LEO Pharma, Novartis, Pfizer, and Sanofi. Dr. Prajapati reports receiving honoraria for advisory boards, consulting, research, and/or speaking from one or more of the following: AbbVie; Actelion; Amgen; Aralez Bio; Arcutis Biotherapeutics; Asana; Aspen Pharmacare; Bausch Health Companies; Boehringer Ingelheim; Bristol Myers Squibb; Celgene; Cipher Pharmaceuticals; Concert Pharmaceuticals; Dermavant Sciences; Eli Lilly and Company; Galderma Laboratories; GlaxoSmithKline; Homeocan; Incyte; Janssen; LEO Pharma; L{\textquoteright}Or{\'e}al; Medexus Pharmaceuticals, Inc; Nimbus Lakshmi; Novartis; Pfizer; Regeneron–Sanofi Genzyme; Sun Pharmaceuticals, Inc; Tribute Pharmaceuticals; UCB; and Valeant. Dr. Lio reports receiving research grants or funding from AbbVie, AOBiome, and Regeneron–Sanofi Genzyme; serving on the speakers bureau for Eli Lilly and Company, Galderma Laboratories, LEO Pharma, Pfizer, and Regeneron–Sanofi Genzyme; and serving on consulting or advisory boards for AbbVie, Almirall, Altus, Amyris, AOBiome, Arbonne, Aslan, Bodewell, Burt{\textquoteright}s Bees, Dermavant Sciences, Dermira, Eli Lilly and Company, Exeltis, Galderma Laboratories, IntraDerm Pharmaceuticals, Johnson & Johnson, LEO Pharma, L{\textquoteright}Or{\'e}al, Menlo Therapeutics, Micros, Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron–Sanofi Genzyme, Theraplex, and Unilever. Correspondence: Peter A. Lio, MD, Northwestern University, Feinberg School of Medicine, 363 W Erie St, Ste 350, Chicago, IL 60654 (peterlio@gmail.com). doi:10.12788/cutis.0471",

year = "2022",

month = mar,

doi = "10.12788/cutis.0471",

language = "English",

volume = "109",

pages = "158--159",

journal = "Cutis",

issn = "0011-4162",

publisher = "Frontline Medical Communications Inc.",

number = "3",

}

TY - JOUR

T1 - Patch Testing on Dupilumab

T2 - Reliable or Not?

AU - Kuzyk, Alexandra

AU - Devani, Alim R.

AU - Prajapati, Vimal H.

AU - Lio, Peter A.

N1 - Funding Information: the Section of Community PCUTIS ediatrics and Section of Pediatric Rheumatology, Department of Pediatrics, University of Calgary. Dr. Lio is from the Department of Dermatology, Northwestern University Feinberg School of Medicine and Medical Dermatology Associates of Chicago, both in Chicago, Illinois. Dr. Kuzyk reports no conflict of interest. Dr. Devani reports receiving honoraria—for serving on advisory boards and speakers bureaus and participating in consultancy meetings and research—from one or more of the following: AbbVie, Arcutis Biotherapeutics, Bausch Health Companies, Galderma Laboratories, Janssen, LEO Pharma, Novartis, Pfizer, and Sanofi. Dr. Prajapati reports receiving honoraria for advisory boards, consulting, research, and/or speaking from one or more of the following: AbbVie; Actelion; Amgen; Aralez Bio; Arcutis Biotherapeutics; Asana; Aspen Pharmacare; Bausch Health Companies; Boehringer Ingelheim; Bristol Myers Squibb; Celgene; Cipher Pharmaceuticals; Concert Pharmaceuticals; Dermavant Sciences; Eli Lilly and Company; Galderma Laboratories; GlaxoSmithKline; Homeocan; Incyte; Janssen; LEO Pharma; L’Oréal; Medexus Pharmaceuticals, Inc; Nimbus Lakshmi; Novartis; Pfizer; Regeneron–Sanofi Genzyme; Sun Pharmaceuticals, Inc; Tribute Pharmaceuticals; UCB; and Valeant. Dr. Lio reports receiving research grants or funding from AbbVie, AOBiome, and Regeneron–Sanofi Genzyme; serving on the speakers bureau for Eli Lilly and Company, Galderma Laboratories, LEO Pharma, Pfizer, and Regeneron–Sanofi Genzyme; and serving on consulting or advisory boards for AbbVie, Almirall, Altus, Amyris, AOBiome, Arbonne, Aslan, Bodewell, Burt’s Bees, Dermavant Sciences, Dermira, Eli Lilly and Company, Exeltis, Galderma Laboratories, IntraDerm Pharmaceuticals, Johnson & Johnson, LEO Pharma, L’Oréal, Menlo Therapeutics, Micros, Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron–Sanofi Genzyme, Theraplex, and Unilever. Correspondence: Peter A. Lio, MD, Northwestern University, Feinberg School of Medicine, 363 W Erie St, Ste 350, Chicago, IL 60654 (peterlio@gmail.com). doi:10.12788/cutis.0471

PY - 2022/3

Y1 - 2022/3

UR - http://www.scopus.com/inward/record.url?scp=85131702541&partnerID=8YFLogxK

U2 - 10.12788/cutis.0471

DO - 10.12788/cutis.0471

M3 - Comment/debate

C2 - 35659147

AN - SCOPUS:85131702541

VL - 109

SP - 158

EP - 159

JO - Cutis

JF - Cutis

SN - 0011-4162

IS - 3

ER -